{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:57:35Z","timestamp":1771678655925,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jinf.2024.106258","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T19:12:41Z","timestamp":1725045161000},"page":"106258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C"],"prefix":"10.1016","volume":"89","author":[{"given":"Thomas R.","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-4610","authenticated-orcid":false,"given":"Kerry Grace","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine S.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-2091","authenticated-orcid":false,"given":"Ludmila","family":"Prokunina-Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106258_bib1","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis","author":"WHO","year":"2016"},{"key":"10.1016\/j.jinf.2024.106258_bib2","series-title":"Combating hepatitis B and C to reach elimination by 2030","author":"WHO","year":"2016"},{"issue":"5","key":"10.1016\/j.jinf.2024.106258_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jinf.2024.106258_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S2468-1253(23)00321-7","article-title":"Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update","volume":"9","author":"Cooke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jinf.2024.106258_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S2468-1253(24)00121-3","article-title":"Urgent action needed to achieve viral hepatitis elimination","volume":"9","author":"The Lancet Gastroenterology & Hepatology","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2024.106258_bib6","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"WHO","year":"2024"},{"issue":"16","key":"10.1016\/j.jinf.2024.106258_bib7","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMe1401508","article-title":"Therapy for hepatitis C \u2014 the costs of success","volume":"370","author":"Hoofnagle","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jinf.2024.106258_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106258_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-018-1162-z","article-title":"Pathways to ensure universal and affordable access to hepatitis C treatment","volume":"16","author":"Douglass","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jinf.2024.106258_bib10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital signs: hepatitis C treatment among insured adults \u2014 United States, 2019\u20132020","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.jinf.2024.106258_bib11","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106258_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jinf.2024.106258_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.jinf.2024.106258_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/ofid\/ofu110","article-title":"Subgroup differences in response to 8 weeks of ledipasvir\/sofosbuvir for chronic hepatitis C","volume":"1","author":"O'Brien","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2024.106258_bib15","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1053\/j.gastro.2017.06.069","article-title":"IFNL4 genotype is associated with virologic relapse after 8-week treatment with sofosbuvir, velpatasvir, and voxilaprevir","volume":"153","author":"O\u2019Brien","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jinf.2024.106258_bib16","series-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"WHO","year":"2018"},{"issue":"10","key":"10.1016\/j.jinf.2024.106258_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004681","article-title":"Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4)","volume":"10","author":"Key","year":"2014","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1016\/j.jinf.2024.106258_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40265-016-0684-y","article-title":"Eight- or 12-week treatment of hepatitis C with ledipasvir\/sofosbuvir: real-world experience in a large integrated health system","volume":"77","author":"Lai","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jinf.2024.106258_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/oxfordjournals.aje.a115074","article-title":"Logistic regression analsis and efficient design for two-stage studies","volume":"128","author":"Cain","year":"1988","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.jinf.2024.106258_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jinf.2024.106258_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2017.11.009","article-title":"Real-world effectiveness of 8-week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C","volume":"68","author":"Buggisch","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jinf.2024.106258_bib22","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/hep.29005","article-title":"Eight weeks of ledipasvir\/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection","volume":"65","author":"Kowdley","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jinf.2024.106258_bib23","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/hep.29057","article-title":"Race or genetic makeup for hepatitis C virus treatment decisions?","volume":"65","author":"O'Brien","year":"2017","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jinf.2024.106258_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/jir.2023.0022","article-title":"IFNL4 genotype frequencies in Asian populations support shorter duration therapy with sofosbuvir-based hepatitis C virus regimens to increase the number cured","volume":"43","author":"O'Brien","year":"2023","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.jinf.2024.106258_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21765","article-title":"Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000","volume":"46","author":"Tseng","year":"2007","journal-title":"Hepatology"},{"issue":"suppl_3","key":"10.1016\/j.jinf.2024.106258_bib26","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","article-title":"Natural history and management of hepatitis C: does sex play a role?","volume":"209","author":"Baden","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106258_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.28292","article-title":"No scientific basis to restrict 8 weeks of treatment with ledipasvir\/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU\/mL","volume":"63","author":"O'Brien","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2024.106258_bib28","unstructured":"US Food Drug Administration CfDEaR. Statistical Review and Evaluation, NDA #: 205834 (Sofosbuvir and ledipasvir fixed-dose combination). In: Center for Drug Evaluation and Research UFDA, editor; 2014. p. 28."},{"issue":"3","key":"10.1016\/j.jinf.2024.106258_bib29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"issue":"27","key":"10.1016\/j.jinf.2024.106258_bib30","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106258_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81801","article-title":"Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study","volume":"12","author":"Flower","year":"2023","journal-title":"Elife"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:02:05Z","timestamp":1733148125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0163445324001920"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106258","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106258"}}